证券代码：002001 证券简称：新和成 公告编号：2024-025 浙江新和成股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 浙江新和成股份有限公司董事会 2024 年 6 月 19 日 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第五次会议于 2024 年 6 月 13 日以电子邮件方式发出会议通知，于 2024 年 6 月 18 日以现场结 合通讯方式召开，应出席董事 11 名，实际出席董事 11 名，符合《公司法》和《公 司章程》的规定。会议经表决形成决议如下： 会议以 5 票同意，0 票反对，0 票弃权审议通过《关于出售资产暨关联交易 的议案》；关联董事胡柏藩、胡柏剡、石观群、王学闻、王正江、周贵阳回避表 决，本议案已经独立董事专门会议审议通过。 为进一步优化公司资产，完善产业结构，聚焦精细化工主业，提高盈利水平 和资产质量。董事会同意将全资子公司琼海博鳌丽都置业有限公司 100%股权以 人民币 8,279.10 万元的价格出售给控股股东新和成控股集团有限公司。 《关于出售资产暨关联 ...

医药生物 | 证券研究报告 — 调整盈利预测 2024年5月30日 002001.SZ 新和成 买入 维生素及蛋氨酸价格上涨，新项目持续推进 原评级：买入 市场价格:人民币 18.92 公司发布2023年年报，2023年实现营收151.17亿元，同比下降5.13%；实现归母净利润27.04 亿元，同比下降 25.30%；其中 23Q4 实现营收 41.04 亿元，同比增长 2.00%，环比增长 板块评级:强于大市 14.21%；实现归母净利润6.03亿元，同比下降1.02%，环比下降2.42%。公司发布2024年一 季报，24Q1实现营收 44.99亿元，同比增长 24.54%，环比增长 9.61%；实现归母净利润 8.70 本报告要点 亿元，同比增长 35.21%，环比增长 44.21%。公司拟向全体股东每 10股派发 4.50元的现金分 红。看好维生素、蛋氨酸价格上涨带来的业绩增长，新项目持续推进，维持买入评级。  2024 年一季度公司业绩同环比提升，看好 支撑评级的要点 维生素、蛋氨酸价格上涨带来的业绩增  24Q1业绩同环比增长。2023年公司营收及归母净利润同比下降，毛利率为 32.98%（同 ...

Group 1: Project Progress and Planning - The hexanediamine project has received approval, and the pilot test is progressing smoothly [2] - The company plans to invest over 2 billion in the liquid methionine project, with a capacity of 180,000 tons, expected to be completed by the end of this year [2] Group 2: Market Insights and Pricing Strategies - Vitamin product prices have shown a month-on-month improvement, with a positive market outlook for Q2 [2] - The company has already raised the price of VA and will adjust VE pricing based on market conditions [2] Group 3: Industry Outlook and Production Capacity - Global demand for methionine is expected to grow by 3-4% annually, with the company maintaining a production capacity of 300,000 tons [2] - The company is focusing on cost reduction and technical improvements at the Heilongjiang base, which has faced losses due to high initial investments and weak vitamin prices [3] Group 4: Future Development and Capital Expenditure - The company aims to continue investing in new projects and products while upgrading existing ones to enhance product value [3] - The flavor and fragrance segment is expected to see stable growth, with plans for expansion in product variety and volume [3]

Investment Rating - The report maintains an "Outperform" rating for the company, indicating a positive outlook for its stock performance relative to the market [7]. Core Insights - The company's performance in 2023 met expectations, with a notable rebound in the nutrition segment and steady expansion of its "Chemical+" and "Biological+" platforms [7]. - The company reported a revenue of 15.117 billion yuan in 2023, a year-on-year decrease of 5.13%, and a net profit of 2.704 billion yuan, down 25.3% year-on-year [7]. - In Q1 2024, the company achieved a revenue of 4.499 billion yuan, reflecting a year-on-year increase of 24.54%, and a net profit of 870 million yuan, up 35.21% year-on-year [7]. Summary by Sections Financial Performance - The company reported a total revenue of 15.117 billion yuan in 2023, with a net profit of 2.704 billion yuan [8]. - For Q1 2024, the revenue was 4.499 billion yuan, and the net profit was 870 million yuan, indicating strong growth compared to the previous year [8]. - The average gross margin for 2023 was 32.98%, down 3.96 percentage points year-on-year [7]. Product Segments - The nutrition segment generated revenue of 9.867 billion yuan in 2023, down 9.9% year-on-year, with a gross margin of 29.91% [7]. - The flavor and fragrance business saw revenue growth of 10.35% year-on-year, reaching 3.274 billion yuan, with a gross margin of 50.51% [7]. - The new materials segment reported revenue of 1.202 billion yuan, up 3.1% year-on-year [7]. Market Trends - The vitamin market showed signs of recovery in Q1 2024, with average prices for key products increasing compared to the previous quarter [7]. - The company is actively expanding its production capacity and investing in new projects, including a joint venture for liquid methionine production [7]. Future Projections - The company forecasts net profits of 4.157 billion yuan for 2024, 5.045 billion yuan for 2025, and 6.041 billion yuan for 2026, with corresponding PE ratios of 15X, 12X, and 10X [8].

证券代码：002001 证券简称：新和成 公告编号：2024-023 浙江新和成股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截至本公告日，浙江新和成股份有限公司（以下简称"本公司"或"公司"） 总股本为 3,090,907,356 股，公司回购专用证券账户持有公司股份 17,485,676 股， 根据《上市公司股份回购规则》的规定，回购专用证券账户股份不享有利润分配 和资本公积金转增股本的权利。本次权益分派实施后，按公司总股本（含回购股 份）折算每 10 股现金分红（含税）比例及除权除息参考价如下： 公司本次实际现金分红总金额（含税）=实际参与分配股本×分配比例，即 1,383,039,756.00元（含税）=3,073,421,680股×0.45元/股（含税）；按公司总股本 （含回购股份）折算的每10股现金分红（含税）比例=本次实际现金分红总金额 ÷总股本（含回购股份）×10，即4.474542元（含税）=1,383,039,756.00（含税） ÷3,090,907,356股×10 本次权益分 ...

证券代码：002001 证券简称：新和成 公告编号：2024-024 浙江新和成股份有限公司 关于募集资金专户销户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2017〕1684 号文核准，并经深圳证券 交易所同意，本公司由主承销商中信建投证券股份有限公司采用非公开发行方式， 向特定对象非公开发行人民币普通股（A 股）股票 17,500 万股，发行价为每股 人民币 28.00 元，共计募集资金 490,000 万元，坐扣承销和保荐费用 3,000 万元 （含税）后的募集资金为 487,000 万元，已由主承销商中信建投证券股份有限公 司于 2017 年 12 月 7 日汇入本公司募集资金监管账户。另扣除律师费、审计费和 验资费等其他发行费用 462.26 万元（不含税）后，并考虑已由主承销商坐扣承销 费和保荐费的可抵扣增值税进项税额人民币 169.81 万元，本次募集资金净额为 486,707.55 万元。上述募集资金到位情况业经天健会计师事务所（特殊普通合伙） 验证，并由其出具《验资报告》 ...

法律意见书 浙江天册律师事务所 关于 浙江新和成股份有限公司 2023 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江新和成股份有限公司 2023 年年度股东大会的 法律意见书 编号：TCYJS2024H0700 号 致：浙江新和成股份有限公司 （一）经本所律师查验，新和成本次股东大会由董事会提议并召集，本次股 东大会会议通知已于 2024 年 4 月 23 日在《证券时报》《中国证券报》《上海证 券报》以及"巨潮资讯网"www.cninfo.com.cn 上公告。 （二）根据本次股东大会的议程，提请本次股东大会审议的议题为： 1、《2023 年度董事会工作报告》； 2、《2023 年度监事会工作报告》； 3、《2023 年年度报告及摘要》； 法律意见书 4、《2023 年度财务决算报告》； 根据会议通知，本次现场会议召开的时间为 2024 年 5 月 15 日（星期三）14 点 30 分，召开地点为新和成一楼会议室（浙江省新昌县七星街道新昌大道西 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 证券代码：002001 证券简称：新和成 公告编号：2024-022 浙江新和成股份有限公司 2023 年年度股东大会决议公告 本次会议召开期间未增加、否决或变更提案的情况。 一、会议召开和出席情况 1、会议召集人：公司董事会 2、会议方式：本次股东大会采取现场投票与网络投票相结合的方式 3、现场会议时间：2024 年 5 月 15 日（星期三）14:30 4、现场会议地点：公司总部会议室（浙江省新昌县七星街道新昌大道西路 418 号） 5、现场会议主持人：董事长胡柏藩先生 6、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2024年5月15日上午9:15-9:25、9:30－11:30，下午13:00－15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2024年5月15日上午9:15至下午 15:00期间的任意时间。 7、本次会议的召集、召开与表决程序符合有关法律法规和《公司章程》的 规定。 二、会议出席情况 1、会议出席的情况：参加本次现场会议及网络投票的股东和 ...

Group 1: Company Performance - In 2023, the company achieved a revenue of CNY 15.117 billion and a net profit of CNY 2.704 billion [2] - In Q1 2024, the company reported a revenue of CNY 4.499 billion, representing a year-on-year growth of 24.54% [2] - The net profit for Q1 2024 was CNY 0.870 billion, with a year-on-year increase of 35.21% [3] Group 2: Business Development Strategy - The company focuses on "integration, series, and collaboration" as its development philosophy, targeting the health and new materials sectors [3] - The strategic goal is to establish a smart manufacturing system and become a leading functional chemicals enterprise [3] Group 3: Methionine Business Insights - Global demand for methionine in 2023 was approximately 1.6 million tons, with a year-on-year growth of 3.2% [3] - Domestic demand reached about 430,000 tons, increasing by 7.5% [3] - The company has a production capacity of 300,000 tons/year for methionine, equipped with smart technology [3] Group 4: New Materials Development - The company is advancing in PPS (special engineering plastics) with a leading global market share [3] - The nylon new materials project is included in Zhejiang's major industrial projects and is currently under preliminary construction [3] Group 5: Investor Q&A Highlights - The company plans to continue investing in new projects while enhancing existing products through technological upgrades [4] - The outlook for vitamin prices remains optimistic, with current prices at a low point and expected fluctuations in the future [4] - The company is confident in the methionine market, anticipating gradual capacity digestion due to increasing domestic demand [4] - Future plans include expanding the product line in bio-fermentation and enhancing competitiveness in the nylon industry [4][5]

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expectation to outperform the benchmark index by over 20% in the next six months [1][4][16]. Core Views - The company's revenue for Q1 2024 reached 4.499 billion yuan, a year-on-year increase of 24.54% and a quarter-on-quarter increase of 9.61%. The net profit attributable to shareholders was 870 million yuan, with a year-on-year increase of 35.21% and a quarter-on-quarter increase of 44.21% [1]. - The increase in methionine sales volume and price contributed significantly to profit growth in Q1 2024. The average price of methionine in Q1 was 21.79 yuan/kg, up 22.55% year-on-year and 2.75% quarter-on-quarter [1]. - Vitamin prices have reached a turning point, with the vitamin price index at 82.64 in Q1 2024, reflecting a quarter-on-quarter increase of 4.15%. The prices of key products like VA and VE have risen by 18.88% and 22.81% respectively from their 2023 lows [1]. - The company has a rich project reserve, including a 4,000 tons/year cysteine project and a 30 billion yuan investment in a new phosphorous amino acid project, which will inject new growth momentum into the company [1]. Financial Summary - The company is expected to achieve net profits of 3.908 billion yuan, 4.762 billion yuan, and 5.189 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 44.5%, 21.8%, and 9.0% [2][8]. - The projected PE ratios for 2024, 2025, and 2026 are 15, 12, and 11 respectively, with a target price set at 22.68 yuan based on an 18x PE for 2024 [1][4].